FindMyKOL
Clinical trialNCT02743351CompletedPhase 1/PHASE2Interventional

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

SponsorFate TherapeuticsEnrollment96Acute Graft-versus-host DiseaseAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelogenous LeukemiaHematologic MalignanciesMyelodysplastic Syndromes
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a Phase 1, non-randomized, open-label/Phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic hematopoietic cell transplantation (HCT) in adult subjects aged 18 years and older with hematologic malignancies. A total of 88 study subjects were treated in the trial at approximately 15 centers in the US.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama

    Birmingham, Alabama, United States

  • City of Hope

    Duarte, California, United States

  • University of California, San Diego (ucsd) Moores Cancer Center

    San Diego, California, United States

  • University of Chicago

    Chicago, Illinois, United States

  • Indiana Blood and Marrow Transplant

    Indianapolis, Indiana, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan, United States

  • Weill Cornell Medicine

    New York, New York, United States

  • Jewish Hospital

    Cincinnati, Ohio, United States

  • the Ohio State University

    Columbus, Ohio, United States

  • Oregon Health & Science University

    Portland, Oregon, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, United States

  • Texas Transplant Institute

    San Antonio, Texas, United States

  • Huntsman Cancer Institute (university of Utah)

    Salt Lake City, Utah, United States

  • Virginia Commonwealth University

    Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Control ArmProTmune
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Dec 2016
Primary completion
4 Dec 2020
Completion
5 Nov 2021
Last update posted
8 Feb 2023
Registered enrollment
96
Registry id
NCT02743351
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.